JW LIFESCIENCE CORPORATION: debt-to-equity, ROE and more
KOSPI, Legal name JW LIFESCIENCE CORPORATION
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 44.3%
- Equity ratio
- 69.3%
- ROE
- 13.0%
- Op. margin
- 12.9%
- Rev. growth
- 15.9%
- Interest coverage
- n/a
Condition flags
- Operating profit for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
| Fiscal year | Cash dividend per share | Payout ratio |
|---|---|---|
| 2025 | ₩550 | 29.8% |
| 2024 | ₩500 | 17.6% |
| 2023 | ₩500 | 27.5% |
Cash dividends for 3 straight years (only the 3 years OpenDART returns).
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 67.3% | 59.8% | 9.3% | 16.7% | n/a |
| FY2022 consolidated | 80.2% | 55.5% | 10.7% | 14.3% | 11.3% |
| FY2023 consolidated | 60.5% | 62.3% | 17.7% | 14.9% | 9.5% |
| FY2024 consolidated | 62.3% | 61.6% | 21.9% | 16.1% | 7.5% |
| FY2025 consolidated | 44.3% | 69.3% | 13.0% | 12.9% | 15.9% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩169.8B | ₩188.9B | ₩206.9B | ₩222.5B | ₩257.8B |
| Operating profit | ₩28.4B | ₩27.1B | ₩30.9B | ₩35.9B | ₩33.2B |
| Pre-tax income | ₩17.5B | ₩20.8B | ₩33.7B | ₩59.0B | ₩31.7B |
| Net income | ₩12.2B | ₩15.0B | ₩28.1B | ₩44.0B | ₩28.6B |
| Total assets | ₩218.7B | ₩252.9B | ₩255.8B | ₩325.3B | ₩318.2B |
| Total liabilities | ₩88.0B | ₩112.6B | ₩96.4B | ₩124.9B | ₩97.6B |
| Total equity | ₩130.8B | ₩140.3B | ₩159.4B | ₩200.4B | ₩220.6B |
| Paid-in capital | ₩39.6B | ₩39.6B | ₩39.6B | ₩39.6B | ₩39.6B |
| Debt/equity (source value) | 67.3% | 80.2% | 60.5% | 62.3% | 44.3% |
Company outline (FSC)
- Market
- KOSPI
- Fiscal year end
- Dec
- Founded
- 1994-05-10
- Listed
- 16/10/27
- Employees
- 319
- Auditor
- 한영회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1350110057395
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for JW생명과학Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.